{"id":"ce-mpa","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Breast tenderness"},{"rate":null,"effect":"Breakthrough bleeding"},{"rate":null,"effect":"Venous thromboembolism"}]},"_chembl":{"chemblId":"CHEMBL5970339","moleculeType":null,"molecularWeight":"442.92"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The estrogen component suppresses follicle-stimulating hormone (FSH) and luteinizing hormone (LH), preventing ovarian follicle development and ovulation. The progestin component further inhibits LH surge, thickens cervical mucus to impede sperm transport, and alters the endometrium to prevent implantation. Together these mechanisms provide contraceptive efficacy.","oneSentence":"CE/MPA is a combined oral contraceptive containing conjugated estrogens and medroxyprogesterone acetate that prevents ovulation and alters the uterine environment to inhibit pregnancy.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:05:07.469Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Contraception"},{"name":"Menstrual cycle regulation"}]},"trialDetails":[{"nctId":"NCT07488949","phase":"NA","title":"Doxycycline and Progestin Therapy for Chronic Endometritis(CE) in Patients With Recurrent Reproductive Failure(RRF)","status":"RECRUITING","sponsor":"Fang Wang","startDate":"2024-04-09","conditions":"Chronic Endometritis","enrollment":1000},{"nctId":"NCT07291648","phase":"NA","title":"Blinding and Adverse Effects of Ultrasonic Vagus Nerve Stimulation (U-VNS) in Tinnitus","status":"COMPLETED","sponsor":"University of Nottingham","startDate":"2025-09-01","conditions":"Tinnitus","enrollment":20},{"nctId":"NCT07091812","phase":"PHASE1, PHASE2","title":"Blinding and Adverse Effects of Ultrasonic Vagus Nerve Stimulation (U-VNS)","status":"COMPLETED","sponsor":"University of Nottingham","startDate":"2024-12-10","conditions":"U-VNS, Sham U-VNS","enrollment":20},{"nctId":"NCT03644225","phase":"NA","title":"Suction Based Characterization of Healthy and Diseased Skin","status":"COMPLETED","sponsor":"Oliver Distler","startDate":"2018-06-11","conditions":"Systemic Sclerosis","enrollment":67},{"nctId":"NCT00745108","phase":"PHASE3","title":"Tibolone Endometrium Study (Study 32972)(P06470)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2001-10-01","conditions":"Postmenopausal Women","enrollment":32},{"nctId":"NCT00242710","phase":"PHASE3","title":"Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations In Postmenopausal Women","status":"COMPLETED","sponsor":"Pfizer","startDate":"2005-09","conditions":"Endometrial Hyperplasia, Osteoporosis","enrollment":1083}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":23,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Premarin","Provera"],"phase":"phase_3","status":"active","brandName":"CE/MPA","genericName":"CE/MPA","companyName":"Organon and Co","companyId":"organon-and-co","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CE/MPA is a combined oral contraceptive containing conjugated estrogens and medroxyprogesterone acetate that prevents ovulation and alters the uterine environment to inhibit pregnancy. Used for Contraception, Menstrual cycle regulation.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}